Attached files
| file | filename |
|---|---|
| EX-99.4 - EX-99.4 - Sorrento Therapeutics, Inc. | d299305dex994.htm |
| EX-99.3 - EX-99.3 - Sorrento Therapeutics, Inc. | d299305dex993.htm |
| EX-99.2 - EX-99.2 - Sorrento Therapeutics, Inc. | d299305dex992.htm |
| 8-K/A - FORM 8-K/A - Sorrento Therapeutics, Inc. | d299305d8ka.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Scilex Pharmaceuticals, Inc.
Malvern, Pennsylvania
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-16370, 333-195487, 333-198307, and 333-213130) and on Form S-3 (Nos. 333-192025, 333-199849, 333-212302, and 333-214897) of Sorrento Therapeutics, Inc. of our report dated April 7, 2016 relating to the financial statements of Scilex Pharmaceuticals Inc., which appear in this Current Report on Form 8-K of Sorrento Therapeutics, Inc.
/s/ BDO USA, LLP
BDO USA, LLP
New York, New York
January 20, 2017
BDO USA, LLP, a Delaware limited liability partnership, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.
BDO is the brand name for the BDO network and for each of the BDO Member Firms.